Goldman Sachs Upgrades Neurocrine Bio. (NBIX) to Buy
Tweet Send to a Friend
Goldman Sachs analyst Chris Shibutani upgraded Neurocrine Bio. (NASDAQ: NBIX) from Neutral to Buy with a price target of $115.00.The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


